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ABSTRACT 
Introduction:  Multiple sclerosis (MS) is an important cause of long standing disability especially in adult 
females. The incidence is more in Europe. In Europe specially in USA and UK the prevalence is about 120/ 
100,000. The annual incidence is around 7 per 100,000, while the life time risk of developing MS is about 1in 
400. The incidence of MS is higher in northern Europeans, and the disease is about twice as common in females. 
Objectives:  To study various ways the patients of multiple sclerosis presented in the department of neurology at 
Royal commission hospital Yanbu, Kingdom of Saudi Arabia. 
Materials and Methods:  This is new as well newly diagnosed patients who presented in the emergency as well as 
outpatient department of neurology at Royal Commission hospital Yanbu, Kingdom of Saudi Arabia. Yanbu is one 
of the biggest industrial city of Saudi Arabia. Duration of study was two years; from January 2011 to December 
2012. The study included 50 patients. We diagnosed 45 patients ourselves and 5 patients were following in the 
neurology OPD. 
Results:  The age range was 17 – 58; 38 patients were females and 2 were males. Most of the affected patients 
were in the age range of 17 – 36. Mean duration of illness was from 1 – 9 years. In most of the patients, the initial 
presentation was weakness and visual loss. Most of the patients were started on interferons and they has very 
good outcome. 
Conclusions:  Multiple sclerosis involves both brain and spinal cord. Early diagnosis and treatment promises 
good outcome and rehabilitation. The new treatment modalities have played revolutionary role in modulating the 
disease. 
Key Words:  Multiple Sclerosis, demyelinating disease. 
Abbreviations:  MS = Multiple sclerosis. 
 
INTRODUCTION 
5Multiple sclerosis is a chronic conditions characte-
rized clinically by episodes of focal disorders of optic 
nerves, spinal cord, and brain, which remit to a vary-
ing extent and recur over a period of many years and 
are usually progressive. The neurological manifesta-
tions are protean, being determined by varied location 
and extent of the demyelinatng foci. Nevertheless, the 
lesions have predilection of a certain parts of CNS, 
resulting the complexes of symptoms and signs and 
imaging appearances that can often be recognized as
distinctive of MS and we will see further on. 
 The typical features of MS are weakness, para-
paresis, paraesthesias, loss of vision, diplopia, nystag-
mus, dysarthria, tremor, ataxia, impairment of deep 
sensation, and bladder dysfunction. The diagnosis may 
be uncertain at the onset and in the early years of dis-
ease, when symptoms and signs point to a lesion in 
only one locus of the nervous system. Later, as the dis-
ease recurs and this disseminates throughout the cen-
tral nervous system, the diagnosis becomes quite cer-
tain. There may be a long period of latency (1 to 10 
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years or longer) between a minor initial symptom, 
which may not even come to medical attention, and 
the subsequent development of more characteristic 
symptoms. In most cases, there is initially a relapsing-
remitting patterns, i.e., the signs and symptoms imp-
rove partially or completely, followed after a variable 
interval by the recurrence of the same abnormality or 
the appearance of new ones in other parts of the ner-
vous system. However, in fewer than half of patients, 
the disease takes the form of steadily progressive cou-
rse, specially patients older than 40 years of age at the 
same time of onset (primary progressive MS). Or, as 
happens more often, an initially relapsing profile later 
becomes steadily progressive (secondary progressive 
MS). 
 A rule that has in the past guided clinicians in that 
the diagnosis of MS was not secure unless there was a 
history of remission and relapse and evidence on exa-
mination of more than one discrete lesion of the CNS. 
The advent of MRI and its capacity to identify clini-
cally in evident lesions has replaced the exclusive 
dependence on clinical criteria of the diagnosis. 
 
OBJECTIVE 
The objective of this study was to see the clinical pre-
sentations of multiple sclerosis in our department. We 
found various ways the disease presented in our depa-
rtment and compared with the other studies. We evalu-
ated old patients and included new patients in the 
study. 
 
MATERIAL AND METHODS 
Study Design 
Retrospective as well as prospective. We had a total of 
forty patients. Out of these thirty five patients were 
new patients that we diagnosed and five patients were 
already following in the neurology OPD. 
 
Duration of Study 
We carried out this study for two years; from January 
2010 to December 2012. 
 
Setting 
Department of neurology Royal Commission hospital 
Yanbu, Kingdom of Saudi Arabia. 
 
Sample Size 
We collected forty patients; 5 patients were already
following in the neurology OPD and 35 patients were 
diagnosed for the first time. 
 
Sample Selection 
Inclusion Criteria 
1. All patients with age 20 years and more were 
included in the study. 
2. All forms of multiple sclerosis were included in 
the study. 
 
Exclusion Criteria 
1- Patients of TIAs were excluded from study. 
2- We carried out autoimmune screening and there-
fore all patients of vasculitis were excluded from 
this study. 
3- Patients of AV malformations may present with 
fluctuating symptoms so these were not included 
in the study. 
 
Data Collection 
40 patients fulfilling McDonald`s criteria were inclu-
ded in the study through OPD department of neuro-
logy, Royal Commission hospital Yanbu, KSA. An 
informed consent was obtained before imaging. The 
demographic information like name, age, sex, and 
address were recorded. No ethical issues were invol-
ved. 
 
RESULTS 
There were forty patients included in this study. All of 
them were investigated for multiple sclerosis, a com-
plete history, through clinical examination, base line 
biochemistry, MRI of the brain/and or spinal cord 
(where both necessary) were done. All patients has 
lumber puncture and CSF was sent for oligoclonal 
bands. The serum was also sent for the same and it 
was made sure that oligoclonal bands were positive 
only in CSF. Autoimmune screening was done to see 
whether ANA was positive or not. Visual evoked pote-
ntials were also done, and latency of P 100 was mea-
sured. An informed consent was taken from the patient 
(as we have already mentioned) Table – 1. 
 
DISCUSSION 
MS is a chronic inflammatory disease of CNS. Multi-
ple plaques of demyelination occur throughout the 
brain and spinal cord, occurring sporadically over
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Table 1: 
 
Clinical Presentation Additional Data Needed 
 2 or more attacks (relapses) 
 2 or more objective clinical lesions 
None; clinical evidence will suffice (additional evidence desireable 
but must be consistent with MS) 
 2 or more attacks 
 1 objective clinical lesion 
Dissemination in space, demonstrated by: 
 MRI 
 or a positive CSF and 2 or more MRI lesions consistent with 
MS 
 Or further clinical attack involving different site 
 1 attack 
 2 or more objective clinical lesions 
Disssemination in time, demonstrated by: 
 MRI 
 or second clinical attack 
 1 attack 
 1 objective clinical lesion 
(monosymptomatic presentation) 
Dissemination in space by demonstrated by: 
 MRI 
 or positive CSF and 2 more MRI lesions consistent with MS 
and 
 
Table 2: 
 
Total number of patients 40 
Female patients 38 
Male patients 2 
Male to female ratio 1:10 
 
Table 3: 
 
Age Range 17-58 Years  
Age Group No. of Patients Percentage (%) 
17 – 26 15 37.5 
27 – 36 12 30 
37 – 46   6 15 
47 – 55   5 12.5 
> 55   1 2.5 
 
Table 4:  Initial Presentation. 
 
Weakness 12 
Visual loss 15 
Sensory loss   1 
Epilepsy   2 
Vertigo   5 
Paraesthesias   1 
Ataxia   3 
Diplopia   1 
 
Table 5:  Initial Presentation. 
 
Age Group (Years) Duration of Illness 
< 6 months   4 
1 – 4 17 
5 – 9   8 
10 – 14   7 
15 – 19   0 
24 – 29   1 
 
Table 6: 
 
Neurological Features Patients 
Weakness 23 
Sensory symptoms 17 
Optic neuritis 18 
Paraesthesias 16 
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Diplopia   6 
Ataxia   9 
Vertigo   7 
Paroxysmal   1 
Bladder   1 
Lhermitte sign   0 
Pain   3 
Dementia   1 
Facial palsy   0 
Impotance   1 
Myokemia   0 
Epilepsy   2 
Falls   2 
Psychiatric manifestations 10 
 
years (dissemination in time and space which is crucial 
for diagnosis). 
 MS is a major cause of disability in young adults 
but recent therapeutic advances mean that it is no 
longer an `untreated` disease. 
 No single group of signs or symptoms is diag-
nostic. A wide variety of possible symptoms may 
occur depending on the anatomical site of lesion; MS 
has been described as the modern, grade imitator. The 
clinical time course of attacks and tempo of evolution 
or symptoms are as good as the symptoms themselves 
in making the diagnosis of MS. 
 
TYPES OF MS 
There are three main clinical patterns (figure) 
1- Relapsing – remitting MS (RRMS) (85 – 90%). 
2- Secondary progressive MS – this late stage of MS 
consists of gradually worsening disability pro-
gressing slowly over years. 75% of patients with 
RRMS will eventually evolve into secondary pro-
gressive phase by35 years after onset. 
3- Primary progressive MS (10 – 15%). The least 
common form of MS, characterized by gradually 
worsening disability without relapses of remis-
sions. 
Different treatment modalities 
Treatment involves to encourage a happy, stress free 
life, if possible. Decrease stress can reduce develop-
ment of new lesions. Minimize disability. If poor diet 
or decrease sun exposure, give vit D to achieve serum 
25 (OH) D levels. Methylprednisolon, for three days 
shortens acute relapses. It does not alter over all pro-
gnosis. Interferons decrease relapse by 30% in active 
relapsing – remitting MS; and decrease lesions accu-
mulation on MRI. Monoclonal antibodies like alemtu-
zumab and natalizumab decrease relapses in RRMS by 
68% and decrease MRI lesions by 92%. There are 
other treatment modalities that are less effective. 
 In our study the age range was 17 – 58 years. Most 
of the patients were females. The duration disease var-
ied from less than 6 months to around 29 years. The 
clinical features included mainly, weakness, sensory 
symptoms, visual loss, altered sensations, dizziness, 
frequent falls, urinary incontinence, and psychiatric 
symptoms. In most of the patients, the duration of ill-
ness was from 1 – 4 years. In our study 12 (30%) pati-
ents presented with weakness, 15 (37.5%) presented 
with visual loss, and one (2.5%) patient presented with 
only sensory symptoms. Two (5%) patients presented 
with fits five (12.5%) presented with vertigo, and one 
(2.5%) patient presented with paraesthesias. Three 
(7.5%) patients presented with ataxia and one (2.5%) 
patient presented with diplopia. 
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